|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rapid and Efficient Gene Modification in Rice and Brachypodium Using TALENs显示文摘 | Qiwei Shan Yanpeng Wang Kunling Chen Zhen Liang Jun Li Yi Zhang Kang Zhang Jinxing Liu Daniel F. Voytas Xuelian Zheng Yong Zhang Caixia Gao | 2013 | Molecular Plant2013，6，4： | 37 |
| 2 | ZFN,TALEN and CRISPR-Cas9 mediated homology directed gene insertion in Arabidopsis:A disconnect between somatic and germinal cells显示文摘Breakthroughs in the generation of programmable sequencespecific nucleases (SSNs),such as zinc finger nucleases (ZFNs), TAL effector nucleases (TALENs)and the RNA-directed nuclease CRISPR-associated protein 9 (Cas9),have greatly increased the ease of plant genome engineering (Voytas,2013;Malzahn et al., 2017).Programmable SSNs introduce a DNA double-strand break (DSB)at a target site in the genome that must be repaired by one of several endogenous DNA repair pathways. | Qiwei Shan Nicholas J.Baltes Paul Atkins Elida R. Kirkland Yong Zhang Joshua A.Ballet Levi G.Lowder Aimee A.Malzahn John C.Haugner Ⅲ Burckhard Seelig Daniel F. Voytas Yiping Qi | 2018 | Journal of Genetics and Genomics2018，45，12： | 9 |
| 3 | COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine显示文摘The World Health Organization(WHO) has declared coronavirus disease 2019(COVID-19) is the first pandemic caused by coronavirus named severe acute respiratory syndrome coronavirus 2(SARS-CoV-2). Currently, there is no effective anti-SARS-CoV-2 drug approved worldwide for treatment of patients with COVID-19. Therapeutic options in response to the COVID-19 outbreak are urgently needed. To facilitate the better and faster development of therapeutic COVID-19 drugs, we present an overview of the global promising therapeutic drugs, including repurposing existing antiviral agents,network-based pharmacology research, antibody development and traditional Chinese medicine. Among all these drugs,we focus on the most promising drugs(such as favipiravir, tocilizumab, SARS-CoV-2 convalescent plasma, hydroxychloroquine, Lianhua Qingwen, interferon beta-1 a, remdesivir, etc.) that have or will enter the final stage of human testing—phase Ⅲ–Ⅳ clinical trials. | Wenyi Guan Wendong Lan Jing Zhang Shan Zhao Junxian Ou Xiaowei Wu Yuqian Yan Jianguo Wu Qiwei Zhang | 2020 | Virologica Sinica2020，35，6： | 5 |
| 4 | Desmoglein 2(DSG2) Is A Receptor of Human Adenovirus Type 55 Causing Adult Severe Community-Acquired Pneumonia显示文摘Human adenovirus type 55(HAdV-B55) is a re-emergent acute respiratory disease pathogen that causes adult communityacquired pneumonia(CAP). Previous studies have shown that the receptor of HAdV-B14, which genome is highly similar with HAdV-B55, is human Desmoglein 2(DSG2). However, whether the receptor of HAdV-B55 is DSG2 is undetermined because there are three amino acid mutations in the fiber gene between HAdV-B14 and HAdV-B55. Here, firstly we found the 3T3 cells, a mouse embryo fibroblast rodent cell line which does not express human DSG2, were able to be infected by HAdV-B55 after transfected with pcDNA3.1-DSG2, while normal 3T3 cells were still unsusceptible to HAdV-B55 infection. Next, A549 cells with h DSG2 knock-down by siRNA were hard to be infected by HAdV-B3/-B14/-B55, while the control siRNA group was still able to be infected by all these types of HAdVs. Finally, immunofluorescence confocal microscopy indicated visually that Cy3-conjugated HAdV-B55 viruses entered A549 cells by binding to DSG2 protein.Therefore, DSG2 is a major receptor of HAdV-B55 causing adult CAP. Our finding is important for better understanding of interactions between adenoviruses and host cells and may shed light on the development of new drugs that can interfere with these processes as well as for the development of potent prophylactic vaccines. | Jing Zhang Kui Ma Xiangyu Wang Yinbo Jiang Shan Zhao Junxian Ou Wendong Lan Wenyi Guan Xiaowei Wu Heping Zheng Bin Yang Chengsong Wan Wei Zhao Jianguo Wu Qiwei Zhang | 2021 | Virologica Sinica2021，36，6： | 4 |
| 5 | Construction and Characterization of a Novel Recombinant Attenuated and Replication-Deficient Candidate Human Adenovirus Type 3 Vaccine:'Adenovirus Vaccine Within an Adenovirus Vector'显示文摘Human adenoviruses(HAd Vs)are highly contagious and result in large number of acute respiratory disease(ARD)cases with severe morbidity and mortality.Human adenovirus type 3(HAd V-3)is the most common type that causes ARD outbreaks in Asia,Europe,and the Americas.However,there is currently no vaccine approved for its general use.The hexon protein contains the main neutralizing epitopes,provoking strong and lasting immunogenicity.In this study,a novel recombinant and attenuated adenovirus vaccine candidate against HAd V-3 was constructed based on a commercially-available replication-defective HAd V-5 gene therapy and vaccine vector.The entire HAd V-3 hexon gene was integrated into the E1 region of the vector by homologous recombination using a bacterial system.The resultant recombinants expressing the HAd V-3 hexon protein were rescued in AD293 cells,identified and characterized by RT-PCR,Western blots,indirect immunofluorescence,and electron microscopy.This potential vaccine candidate had a similar replicative efficacy as the wild-type HAd V-3 strain.However,and importantly,the vaccine strain had been rendered replication-defective and was incapable of replication in A549 cells after more than twentygeneration passages in AD293 cells.This represents a significant safety feature.The mice immunized both intranasally and intramuscularly by this vaccine candidate raised significant neutralizing antibodies against HAd V-3.Therefore,this recombinant,attenuated,and safe adenovirus vaccine is a promising HAd V-3 vaccine candidate.The strategy of using a clinically approved and replication-defective HAd V-5 vector provides a novel approach to develop universal adenovirus vaccine candidates against all the other types of adenoviruses causing ARDs and perhaps other adenovirus-associated diseases. | Yuqian Yan Shuping Jing Liqiang Feng Jing Zhang Zhiwei Zeng Min Li Shan Zhao Junxian Ou Wendong Lan Wenyi Guan Xiaowei Wu Jianguo Wu Donald Seto Qiwei Zhang | 2021 | Virologica Sinica2021，36，3： | 1 |
| 6 | MoO2-graphene nanocomposite as anode material for lithium-ion batteries显示文摘 | Tang Qiwei Shan Zhongqiang Wang Li | 2012 | Elec- trochimica Acta2012，79，： | 1 |
| 7 | Simultaneous edit- ing of three homoeoaUeles in hexaploid bread wheat confers her- itable resistance to powdery mildew显示文摘 | Wang Yanpeng Cheng Xi Shan Qiwei | 2014 | Nature Bioteebnology2014，32，9： | 1 |
| 8 | Pilot Postoperative Ileus Study of Escin in Cancer Patients After Colorectal Surgery显示文摘 | Qiwei Xie Xianglong Zong Baoming Ge Shan Wang Jiafu Ji Yingjiang Ye Lili Pan | 2009 | World Journal of Surgery2009，，： | 1 |
| 9 | Genome editing in rice and wheat using the CRISPR/Cas system显示文摘 | Shan Qiwei Wang Yanpeng Li Jun | 2014 | Nature Protocols2014，9，10： | 1 |
| 10 | Grinding aid-assisted preparation of high-performance carbon-LiMnPO 4显示文摘 | Lingbing Ran Xiaoyan Liu Qiwei Tang Kunlei Zhu Jianhua Tian Jiangyong Du Zhongqing Shan | 2013 | Electrochimica Acta2013，，： | 1 |
| 11 | RNA的poly(A)化修饰为真核细胞提供能量代谢稳态调控的便捷通道显示文摘文章简介本研究首次论证了poly(A)化可作为一个标签,实现真核细胞蛋白质合成的整体把控,而且首次把RNA转运引入到能量代谢稳态调控领域,为能量代谢紊乱相关疾病防治及药物研发提供了新研究视野。 | Peipei Shan Guangjian Fan Lianhui Sun Jinqin Liu Weifang Wang Chen Hu Xiaohong Zhang Qiwei Zhai Xiaoyu Song Liu Cao Yongping Cui 张胜萍 王传贵 | 2018 | 科学新闻2018，0，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员